SPAGNOLO , Francesco

Le terapie a bersaglio molecolare (targeted therapies, TT) e l'immunoterapia con anticorpi immunomodulanti (immune checkpoint blockers, ICB) hanno rivoluzionato la terapia del melanoma metastatico (MM). Sebbene con utilizzo delle TT siano stati ottenuti tassi di risposta superiori al 70%, il tasso di recidiva e lo sviluppo di resistenze è...

Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation and the introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. However, most patients...

No description

Vasculitic ulcers are caused by numerous disorders and may be chronic if not well treated. Various modalities of treatment, both medical and surgical, are available. We describe the case of a 63-year-old patient with a vasculitic ulcer treated with platelet-derived growth factors and noncultured autologous cell suspension collected by an...

BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free survival, compared to dabrafenib monotherapy,...